All In Biotech

Drug Trial Radar · NCT05517447

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

109

Actual

Start

Nov 6, 2022

Primary completion

Apr 2, 2026

Study completion Apr 2, 2026

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Aug 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.

Conditions

  • Thyroid Eye Disease

Interventions

  • Observational cohort studyOther

    Observational cohort study

  • BatoclimabDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of proptosis response off treatment in study eye in batoclimab responder participants in the feeder studiesTime frame: Up to Week 24

Locations

55 sites in 14 countries. Site status is shown where the registry gives one.

  • Site Number - 1520

    Glendora, California

  • Site Number - 1501

    Aurora, Colorado

  • Site Number - 1526

    Livonia, Michigan

  • Site Number - 1513

    Rochester, Minnesota

  • Site Number - 1540

    Las Vegas, Nevada

  • Site Number - 1508

    Houston, Texas

  • Site Number - 1558

    Mesquite, Texas

  • Site Number - 1511

    Morgantown, West Virginia

  • Site Number - 1518

    Milwaukee, Wisconsin

  • Site Number - 7565

    Sydney, Australia

  • Site Number - 4671

    Bruges, Belgium

  • Site Number - 4672

    Brussels, Belgium

  • Site Number - 4673

    Brussels, Belgium

  • Site Number - 4670

    Ghent, Belgium

  • Site Number - 3454

    Tbilisi, Georgia

  • Site Number - 3455

    Tbilisi, Georgia

  • Site Number - 3450

    Tbilisi, Georgia

  • Site Number - 3451

    Tbilisi, Georgia

  • Site Number - 7550

    Budapest, Hungary

  • Site Number - 7552

    Pécs, Hungary

  • Site Number - 4764

    Afula, Israel

  • Site Number - 4761

    Jerusalem, Israel

  • Site Number - 4762

    Petah Tikva, Israel

  • Site Number - 4760

    Ramat Gan, Tel Aviv, Israel

  • Site Number - 6207

    Catania, Italy

  • Site Number - 6204

    Milan, Italy

  • Site Number - 6203

    Milan, Italy

  • Site Number - 6205

    Naples, Italy

  • Site Number - 6209

    Palermo, Italy

  • Site Number - 6201

    Pisa, Italy

  • Site Number - 6202

    Rome, Italy

  • Site Number - 9301

    Ogre, Latvia

  • Site Number - 9300

    Riga, Latvia

  • Site Number - 9302

    Ventspils, Latvia

  • Site Number - 7570

    Christchurch, New Zealand

  • Site Number - 3101

    Krakow, Poland

  • Site Number - 3104

    Lublin, Poland

  • Site Number - 3105

    Lublin, Poland

  • Site Number - 3107

    Gliwice, Silesian Voivodeship, Poland

  • Site Number - 1990

    San Juan, Puerto Rico

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.